Search results
Results from the WOW.Com Content Network
Diabetic neuropathy is one of the most prevalent chronic complications in adults with type 1 or type 2 diabetes while also affecting individuals with prediabetes and young people with diabetes, with an estimated lifetime prevalence exceeding 50% (1 – 4).
Patients with diabetic neuropathy should be treated with a systematic, stepwise approach that includes glycemic control and control of the metabolic syndrome, education and counseling on foot care and safety measures, and symptomatic treatment of pain, when present.
Diabetic neuropathy is a diagnosis of exclusion. Nondiabetic neuropathies may be present in patients with diabetes and may be treatable by specific measures. A number of treatment options exist for symptomatic diabetic neuropathy. Up to 50% of diabetic peripheral neuropathies may be asymptomatic.
The treatment you'll need depends on the neuropathy-related complications you have: Urinary tract problems. Some drugs affect bladder function, so your health care provider may recommend stopping or changing medications.
The updated guideline from the American Academy of Neurology supports offering tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers to reduce pain from diabetic neuropathy.
This is a summary of the American Academy of Neurology (AAN) practice advisory update, “Oral and topical treatment of painful diabetic polyneuropathy practice guideline update summary,” which was published in Neurology® online on December 27, 2021, and appears in the January 4, 2022, print issue.
Diabetic sensorimotor polyneuropathy represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective. 1,2 Painful diabetic neuropathy (PDN) affects 16% of patients with diabetes, and it is frequently unreported (12.5%) and ...